Tocilizumab Use in a Chronic Hemodialysis Patient for the Management of COVID-19-Associated Pneumonia and Acute Respiratory Distress Syndrome
Novel coronavirus disease 2019 (COVID-19) is a highly infectious, rapidly spreading viral disease. As of writing this article, there are over 4.4 million people affected by COVID-19, and unfortunately, 300,000 have succumbed to the infection. In this article, we address a particularly more susceptib...
Saved in:
Main Authors: | Sudeendra Gupta, Rakesh Madhyastha, Fadi Hamed, Maher Balkis, Wasim El Nekidy, Nizar Attallah |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | Case Reports in Nephrology |
Online Access: | http://dx.doi.org/10.1155/2020/8829309 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-Life Use of Tocilizumab in the Treatment of Severe COVID-19 Pneumonia
by: Ruth Alex, et al.
Published: (2022-01-01) -
Endocan, a Risk Factor for Developing Acute Respiratory Distress Syndrome among Severe Pneumonia Patients
by: Jun Ying, et al.
Published: (2019-01-01) -
Chronic-Alcohol-Abuse-Induced Oxidative Stress in the Development of Acute Respiratory Distress Syndrome
by: Yan Liang, et al.
Published: (2012-01-01) -
Sarcoidosis Presenting as Acute Respiratory Distress Syndrome
by: Bilal Haider Lashari, et al.
Published: (2018-01-01) -
The Promising Effect of Tocilizumab on Chronic Antibody-Mediated Rejection (cAMR) of Kidney Transplant
by: Łukasz Świątek, et al.
Published: (2025-01-01)